Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2024)

Solid Biosciences' Total Current Liabilities history spans 8 years, with the latest figure at $22.9 million for Q3 2024.

  • For Q3 2024, Total Current Liabilities rose 44.5% year-over-year to $22.9 million; the TTM value through Sep 2024 reached $22.9 million, up 44.5%, while the annual FY2023 figure was $14.5 million, 35.5% down from the prior year.
  • Total Current Liabilities for Q3 2024 was $22.9 million at Solid Biosciences, up from $14.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $24.5 million in Q4 2020 and bottomed at $12.9 million in Q1 2020.
  • The 5-year median for Total Current Liabilities is $20.3 million (2023), against an average of $18.8 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 77.24% in 2021 before it plummeted 35.5% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $24.5 million in 2020, then dropped by 3.59% to $23.6 million in 2021, then dropped by 4.63% to $22.5 million in 2022, then tumbled by 35.5% to $14.5 million in 2023, then surged by 57.43% to $22.9 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Total Current Liabilities are $22.9 million (Q3 2024), $14.7 million (Q2 2024), and $14.3 million (Q1 2024).